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223 Abstract
24 Enteric methane formation in ruminants is one of the major contributors to 
25 climate change. We have reported that supplementation of naturally produced 
26 lovastatin reduced methane emissions in goats without adversely affecting 
27 rumen fermentation and animal performance, except that at higher level, 
28 lovastatin can have a negative effect on the palatability of the formulated diet. 
29 As statins are associated with the development of muscle-related adverse 
30 effects at higher than recommended therapeutic doses, this study was 
31 conducted to examine the effects of lovastatin on the histology and proteome 
32 profile of goat skeletal muscle. A total of 20 intact male Saanen goats were 
33 randomly assigned in equal numbers to 4 groups, and fed with a total mixed 
34 ration containing 50% rice straw, 22.8% concentrates and 27.2% of various 
35 proportions of untreated or treated palm kernel cake (PKC) to achieve the target 
36 daily intake levels of 0 (Control), 2 (Low), 4 (Medium) or 6 (High) mg 
37 lovastatin/kg body weight (BW). Histological examination discovered that the 
38 longissimus thoracis et lumborum muscle of animals from the Medium and High 
39 treatment groups showed abnormalities in terms of necrosis, degeneration, 
40 interstitial space and vacuolation. Western blot analysis conducted on the 
41 myosin heavy chain showed that the immunoreactivity of myosin heavy chain in 
42 the High treatment group was significantly lower than the Control, Low and 
43 Medium treatment groups. Comparisons between control and lovastatin-treated 
44 groups demonstrated that lovastatin supplementation induced complex 
45 modifications to the protein expression patterns of the longissimus thoracis et 
46 lumborum muscle of the goat. There were 30, 26 and 24 proteins differentially 
47 expressed in Low, Medium and High treatment groups respectively, when 
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348 compared to the Control group. Supplementation of lovastatin down-regulated 
49 proteins involved in carbohydrate and creatine metabolism, indicative of 
50 reduced energy production, and may have contributed to the skeletal muscle 
51 damage. Supplementation of naturally produced lovastatin induced muscle 
52 damage in longissimus thoracis et lumborum muscle of goats with increasing 
53 dosages, particularly at 6mg/kg BW. In addition, proteomics analysis revealed 
54 that lovastatin supplementation induced complex modifications to the protein 
55 expressions of skeletal muscle of goats which may have contributed to the 
56 observed skeletal muscle damage. Present study suggested that 
57 supplementation of naturally-produced lovastatin at 6mg/kg BW could adversely 
58 affecting health and wellbeing of the animals.
59
60 Introduction
61 Methane gas is one of the major greenhouse gases that is contributing to 
62 climate change. Livestock production has been reported to contribute 
63 approximately 18% of methane emissions and 9% of carbon dioxide production 
64 [1], which results primarily from the enteric fermentation of feeds [2]. Enteric 
65 methane formation results from the activity of complex interactions of anaerobic 
66 bacteria which together enable degradation of ruminant feeds and 
67 methanogenic archaea which help remove metabolic hydrogen in the rumen [3]. 
68 Despite the importance of methanogenesis in maintaining low partial pressure 
69 of hydrogen required for efficient ruminal fermentation, the formation of 
70 methane also represents 2-12% loss of gross dietary energy [4]. Hence, 
71 extensive research efforts are focused on the development of strategies to 
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472 modify ruminal fermentation for reduction of methane emissions [5] as well as 
73 better feed utilization [6].
74
75 Among the potential strategies for mitigating methane emissions, 
76 supplementation of feed additives such as ionophores [7], organic acids [8], 
77 fatty acids [9], methyl coenzyme M reductase inhibitors [10], vaccine [11] and 
78 oils [12] have been extensively researched. However, many of these strategies 
79 have limited application due to their negative effect(s) on human and animal 
80 health, animal performance parameters and economical acceptance [13]. 
81 Supplementation of naturally produced lovastatin is a promising approach for 
82 mitigating methane emissions. 
83
84 Lovastatin (C24H36O5, M.W. 404.55) is a secondary product during the 
85 secondary phase (idiophase) of fungal growth. It is a competitive inhibitor of 3-
86 hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is a key 
87 enzyme in the cholesterol production pathway [14]. Inhibition of HMG-CoA 
88 reductase will mediate the suppression of cholesterol synthesis and cell 
89 membrane formation in methanogenic Archaea. A previous study has shown 
90 that significant reduction in growth and activity of methanogenic Archaea using 
91 lovastatin without any negative effect on cellulolytic bacteria [15]. In addition, 
92 naturally produced lovastatin has been shown to mitigate methane gas 
93 emissions, while simultaneously enhancing digestibility of feed [16]. 
94
95 A previous study has reported the effects of naturally produced lovastatin from 
96 fermented-Monascus purpureus red rice powder on cattle [17]. High dose of 
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597 fermented-Monascus purpureus red rice powder (100g/day and above) 
98 supplementation adversely affected dry matter intake and ruminant physiology. 
99 We have recently reported that supplementation of naturally produced lovastatin 
100 in goats as being capable of mitigating methane emissions effectively without 
101 adversely affecting digestion and rumen fermentation, except that animals fed 
102 the highest level (6 mg/kg BW) had lower appetite [18]. Statins have been 
103 associated with the development of muscle-related adverse effects, however 
104 the effects of lovastatin on the skeletal muscle in goats have not been studied. 
105 Therefore, this follow-up study was conducted to examine the effects of 
106 lovastatin on the histology and proteome profile of the goat skeletal muscle from 
107 the above study to further elucidate whether supplementation of lovastatin 
108 affects the health and wellbeing of the goats.
109
110 Material and Methods
111 Animals and management
112 This study was approved by the Animal Care and Ethics Committee of the 
113 Universiti Putra Malaysia (UPM/IACUC/AUP-R0087/2015). Detail protocols of 
114 the study have been reported [18]. Briefly, twenty intact male Saanen goatsof 4-
115 5 months old with average live weight of 26 ± 3.4 kg were used in the 12-week 
116 feeding trial. The animals were randomly assigned in equal numbers and fed a 
117 total mixed ration containing 50% rice straw, 22.8% concentrates and 27.2% of 
118 various proportions of untreated or treated PKC to achieve the target daily 
119 intake level of 0 (Control), 2 (Low), 4 (Medium) or 6 (High) mg lovastatin/kg BW. 
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6120 The lovastatin was produced by solid state fermentation using PKC (palm 
121 kernel cake) and Aspergillus terreus (ATCC 74135) [18].
122
123 Slaughtering and sample collection
124 At the end of feeding trial, the animals were humanely slaughtered according to 
125 the standard protocol of halal (Muslim) slaughtering (MS1500:2009). 
126 Immediately after skin removal and evisceration, longissimus thoracis et 
127 lumborum muscle was collected from each animal. The muscle samples 
128 collected for histology analysis were rinsed with normal saline solution before 
129 fixing in 10% PBS buffered formalin solution. Muscle samples were snapped 
130 frozen with liquid nitrogen for proteomics analysis and kept in -80°C until further 
131 analysis. 
132
133 Histology
134 Muscle samples were removed from the formalin solution, dehydrated in an 
135 increasing ethanol series and routinely processed for paraffin embedding. The 
136 samples were sectioned at 5m and stained with haematoxilin-eosin. From 
137 each muscle, five locations were sectioned and each location was mounted on 
138 a slide. and viewed with a Leica DM LB2 upright light microscope (Leica 
139 microsystems Wetzlar GmbH, Wetzlar, Germany). Three images were captured 
140 from each slide under 20 × magnification using a Leica DFC320 digital camera 
141 connected to a computer which was controlled with Leica IM50 v4.0 software 
142 (Leica microsystems Wetzlar GmbH, Wetzlar, Germany).
143
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7144 The muscle tissues were evaluated for evidence of necrosis, degeneration, 
145 interstitial space and vacuolization. Numerical scores were assigned based on 
146 degree of severity (0 = normal to 5 = severe) according to Gall et al. [19] (Table 
147 1). Histological scores between every treatment groups were compared using 
148 Kruskal-Wallis test. Statistical confidence was considered as P<0.05.
149
150 Table 1. Scoring system used in histological analysis on longissimus 
151 thoracis et lumborum muscle of goats supplemented with naturally 
152 produced lovastatin.
Score Histopathologic injury Percentage
0 Normal 0%
1 Minimal <15%
2 Mild <25%
3 Moderate < 40%
4 Marked >50
153
154 Immunoblot analysis of myofibrillar proteins
155 All muscle samples were pulverized into powder form with pestle and mortar 
156 using liquid nitrogen. Myofibrillar proteins were extracted according to Morzel et 
157 al. [20] with slight modifications. Approximately 100mg of muscle powder was 
158 mixed with 1ml of extraction buffer containing 150mM NaCl, 25mM KCl, 3mM 
159 MgCl2, 4mM EDTA and5μlof protease inhibitor (Calbiochem®) at pH6.5. The 
160 mixture was vortexed for 30s before centrifuging at 500rpm for 5 min. After that, 
161 the supernatant was transferred to a new tube, and centrifuged again at 4340 
162 rpm for 15 mins at 4°C. The resulting pellet was washed twice with 1ml of 
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8163 50mM KCl solution at pH6.4 and once with 1ml of 20mM phosphate buffer at 
164 pH6. The pellet was eventually suspended in Tris-SDS buffer.
165
166 The extracted myofibrillar proteins were separated by sodium dodecyl sulphate-
167 polyacrylamide gel electrophoresis (SDS-PAGE) [21]. The proteins were mixed 
168 with sample loading buffer (62.5mM Tris-HCl at pH6.8, 25% glycerol, 2% SDS, 
169 0.01% (w/v) bromophenol blue and 5% -mercaptoethanol) at ratio of 1: 5 and 
170 incubated at 94C for 5 min. For myosin heavy chain, the proteins were 
171 separated with 4% stacking and 5% resolving gels. Whilst, other proteins were 
172 separated with 4% stacking and 12% resolving gels for troponin T. The SDS-
173 PAGE was conducted at a constant current of 15mA/gel for 15 min, followed by 
174 20mA/gel until the bromophenol blue dye reached the bottom of the gel. 
175
176 Following electrophoresis, the gel was equilibrated in the transfer buffer (25mM 
177 Tris, 192mM glycine and 20% (v/v) methanol at pH 8.3) for 10 min before 
178 blotted for 2 hr at 250mA with voltage limit of 25 V onto a polyvinylidene 
179 difluoride membrane. Membranes were blocked with 5% bovine serum albumin 
180 in TBST buffer (100mM Tris-HCl, 150mM NaCl, 0.05% Tween 20 and 0.05% 
181 SDS) overnight and incubated with primary antibody. For myosin heavy chain, 
182 the membranes were incubated with 1:500 dilution of monoclonal anti-myosin 
183 (skeletal, fast) (M4276, Sigma-Aldrich, USA) and monoclonal anti-myosin 
184 (skeletal, slow) (M8421, Sigma-Aldrich, USA) antibodies in 3% BSA in TBST 
185 buffer. Monoclonal anti-troponin-T antibody (T6277, Sigma-Aldrich, USA) was 
186 used as the primary antibody for troponin-T. After that, the membranes were 
187 washed with TBST buffer for three times and subsequently incubated in 
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9188 1:10,000 dilution of secondary antibody (anti-mouse IgG whole molecule 
189 conjugated with alkaline phosphatase) (A3562, Sigma-Aldrich, USA). The 
190 membranes were then washed with TBST buffer for three times and detected 
191 using AP detection kit (Bio-Rad, USA). Protein bands were visualized using Gel 
192 DocTM XR+ System (Bio-Rad, USA) and quantified with Image LabTM software 
193 (Bio-Rad, USA).
194
195 The difference in the band intensity of myosin heavy chain and actin amongst 
196 the treatment groups were determined statistically using one-way analysis of 
197 variance (ANOVA) at 95% confidence level. The data analysis was conducted 
198 using SAS software (version 9.1, SAS Inst. Inc., U.S.A.). The data is presented 
199 as means ± standard error of means (S.E.M.).
200
201 Liquid chromatography mass spectrometry
202 Crude protein was extracted from each muscle sample. Briefly, 0.2 g of muscle 
203 sample in powder form was mixed with 1ml of cold buffer containing 100mM 
204 Tris, pH 8.3 and 10 µl protease inhibitor (Calbiochem®). The samples were 
205 mixed thoroughly with vortex for 30s and centrifuged at 4°µC for 20min at 
206 15,000 g. The supernatant was carefully collected and the concentration was 
207 determined using the Bradford assay [22]. 
208
209 Each protein sample (100g) was reduced with 50mM DTT at 60C for 60min 
210 and alkylated with 50mM iodoacetamide in the dark for 45 min at room 
211 temperature. Then, proteins were diluted with 50mM ammonium bicarbonate 
212 and digested with trypsin at 37C overnight. The digestion process was 
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213 stopped by adding 0.5% formic acid. Digested peptides were desalted using 
214 C18 ZipTip pipette tips (Millipore, Billerica, USA) according to the supplier’s 
215 instructions, and resuspended in 0.1% formic acid. 
216
217 The purified digested peptides were separated with reverse phase liquid 
218 chromatography using a Dionex Ultimate 3000 RSLCnano system (Thermo 
219 Fisher Scientific) and analyzed by tandem mass spectrometry using Orbitrap 
220 Fusion mass spectrometry (Thermo Fisher Scientific). Peptide samples (2l) 
221 were separated on the EASY-Spray Column Acclaim PepMapTM C18 100A 
222 (2m particle size, 50m id × 25cm; Thermo Fisher Scientific) by a gradient 
223 from 5% to 40% of buffer B (0.1% formic acid in acetonitrile) at 300nL/min flow 
224 over 91 min. The remaining peptides were eluted by a short gradient from 40% 
225 to 95% buffer B in 2 min. 
226
227 The eluting peptides were analyzed using tandem mass spectrometry using 
228 Orbitrap Fusion mass spectrometry. Full scan spectra were collected using the 
229 following parameters: scan range 310-1800 m/z, resolving power of 120,000, 
230 AGC target of 4.0 e5 (400,000), and maximum injection time of 50 ms. The 
231 method consisted of 3 s Top Speed Mode where precursors were selected for a 
232 maximum 3 s cycle. Only precursors with an assigned monoisotopic m/z and a 
233 charge state of 2 – 7 were further analyzed for MS2. All precursors were filtered 
234 using a 20 second dynamic exclusion window and intensity threshold of 5000. 
235 The MS2 spectra were analyzes using the following parameters: rapid scan rate 
236 with a resolving power of 60,000, AGC target of 1.0e2 (100), 1.6 m/z isolation 
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237 window, and a maximum injection time of 250 ms. Precursors were fragmented 
238 by CID and HCD at normalized collision energy of 30% and 28%.
239
240 The raw data obtained was analyzed using Thermo ScientificTM Proteome 
241 DiscovererTM Software Version 2.1 (Thermo Fisher Scientific) with searching 
242 database of goat (Capra hircus) and mammalian downloaded from UniProt. The 
243 parameters for searching were set as follows: missed cleavage: 2; MS1 
244 tolerance: 10ppm; MS2 tolerance: 0.6Da; variable modification: oxidation (M), 
245 deamidation of aspargine (N) and glutamine (Q); and fixed modification: 
246 carbamidomethyl (C). All peptides were validated using the percolator© 
247 algorithm based on q-value less than 1% false discovery rate. 
248
249 Quantitative analysis of the data was analyzed using Perseus version 1.6.0.2 to 
250 identify the differentially expressed proteins in the muscle between the control 
251 and lovastatin-treated groups. Pair-wise comparison between control and each 
252 lovastatin-treated group was conducted using Student T-test. Gene ontology 
253 enrichment analysis and functional annotation of the identified proteins were 
254 performed using Database for Annotation, Visualization and Integrated 
255 Discovery (DAVID) version 6.8 (https://david.ncifcrf.gov) [23]. In addition, the 
256 cell and molecular functions and canonical pathways of these proteins were 
257 identified using Ingenuity® Pathway Analysis (IPA®) (Qiagen, Germany).
258
259 Results
260 Histology
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261 The histological examinations showed that skeletal muscle of animals 
262 supplemented with lovastatin suffered from light to moderate damage (Figure 
263 1). Mild haemorrhage was observed in the Medium treatment group while 
264 skeletal muscle of the High treatment group showed relatively severe 
265 degeneration as compared to other treatment groups. Descriptive data for each 
266 group is shown in Table 2. The Kruskal-Wallis test showed a significant 
267 difference among the four groups. It was observed that the muscle of the 
268 Control group was normal, with no signs of any degeneration. The scores of 
269 necrosis, interstitial space and vacuolization of the Low treatment group were 
270 similar (P>0.05) to the Control group, except the score of degeneration 
271 (P<0.05). When the Medium and High treatment groups compared with the 
272 Control group, the scores of degeneration, necrosis, interstitial space and 
273 vacuolization were significantly different (P<0.05). The scores of necrosis, 
274 interstitial space and vacuolization, but not of degeneration of Low treatment 
275 group, were significantly different (P<0.05) with Medium treatment group. When 
276 comparing the Medium and High treatment groups, only the scores of necrosis 
277 and degeneration were significantly different (P<0.05) between both groups.
278
279 Fig 1. Histological analysis on longissimus thoracis et lumborum muscle 
280 of goats supplemented with naturally produced lovastatin. 
281 Control, Low, Medium and High represent 0, 2, 4 and 6 mg lovastatin/kg BW, 
282 respectively. 
283 Mild haemorrhage was observed in the Medium treatment group. Skeletal 
284 muscle of High treatment group showed relatively severe degeneration as 
285 compared to other treatment groups.
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286 Table 2. Histology scores of longissimus thoracis et lumborum muscle of goats supplemented with naturally produced 
287 lovastatin.
Control Low Medium HighParameters
Median Min Max Median Min Max Median Min Max Median Min Max
Necrosis 0a 0 0 0a 0 0 1b 0 2 3c 1 4
Degeneration 0a 0 0 0b 0 1 0 b 0 2 2c 0 3
Interstitial space 0a 0 0 0 a 0 0 1 b 0 3 1 b 0 3
Vacuolation 0a 0 0 0 a 0 0 1 b 0 2 1 b 0 3
288 Control, Low, Medium and High represent 0, 2, 4 and 6 mg lovastatin/kg BW, respectively. 
289 Data was presented as the median, minimum and maximum of the score.
290 abc = Score within a row with different superscripts differ significantly at p<0.05.
291
292
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293 Expressions of myosin heavy chain and actin
294 The difference in the immunoreactivities of myosin heavy chain and actin of 
295 longissimus thoracis et lumborum muscle in the goats supplemented with 
296 various lovastatin levels is presented in Table 3. There were significant 
297 differences in the expression of myosin heavy chain between the treatment 
298 groups, while the expression of actin was found to be unaffected by lovastatin 
299 supplementation. The immunoreactivities of myosin heavy chain in the High 
300 treatment group were significantly lower than the Control, Low and Medium 
301 treatment groups. In contrast, the immunoreactivities of myosin heavy chain 
302 were similar between the Control, Low and Medium treatment groups.
303
304
305 Expressions of myosin heavy chain and actin
306 The difference in the immunoreactivities of myosin heavy chain and actin of 
307 longissimus thoracis et lumborum muscle in the goats supplemented with 
308 various lovastatin levels is presented in Table 3. There were significant 
309 differences in the expression of myosin heavy chain between the treatment 
310 groups, while the expression of actin was found to be unaffected by lovastatin 
311 supplementation. The immunoreactivities of myosin heavy chain in the High 
312 treatment group were significantly lower than the Control, Low and Medium 
313 treatment groups. In contrast, the immunoreactivities of myosin heavy chain 
314 were similar between the Control, Low and Medium treatment groups.
315
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316 Table 3. Differences in immunoreactivities of myosin heavy chain and 
317 actin in longissimus thoracis et lumborum muscle of goats supplemented 
318 with naturally produced lovastatin.
Protein Control Low Medium High
Myosin heavy chain 0.360.01a 0.360.00a 0.360.01a 0.350.00b
Actin 0.380.00a 0.390.00a 0.390.00a 0.380.00a
319 Control, Low, Medium and High represent 0, 2, 4 and 6 mg lovastatin/kg BW, 
320 respectively. 
321 ab Mean within a row with different superscripts differ significantly at p<0.05.
322
323 Differentially expressed proteins
324 The present study identified approximately 400 proteins in the 
325 longissimus thoracis et lumborum muscle of goat. Comparisons between control 
326 and lovastatin-treated groups demonstrated that lovastatin supplementation 
327 induced complex modifications to the protein expression patterns in the 
328 longissimus thoracis et lumborum muscle of the goat. When the Low treatment 
329 and Control groups were compared, there were 25 proteins down-regulated and 
330 five proteins up-regulated in the Low treatment group (Table 4). When the 
331 Medium treatment and Control groups were compared, 21 proteins were 
332 observed to be down-regulated and five proteins up-regulated (Table 5). When 
333 the Control and High treatment groups were compared, 23 proteins were down-
334 regulated and one protein was up-regulated in the muscle tissue (Table 6).
335
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336 Table 4. Differentially expressed proteins in longissimus thoracis et lumborum muscle of goats supplemented with 2mg 
337 lovastatin/ kg body weight.
UniProt 
Accession
Description Species Coverage # Unique 
Peptides
# AAs1 MW2 
[kDa]
calc. 
pI3
Control Low -Log 
p-value
Difference4
Carbohydrate metabolism
P06733 Alpha-enolase Homo sapiens 24.65 3 434 47.14 7.39 30.04 23.77 5.68 -6.27
P00883 Fructose-bisphosphate aldolase 
A
Oryctolagus 
cuniculus
59.34 5 364 39.32 8.09 34.17 27.00 5.36 -7.17
P05065 Fructose-bisphosphate aldolase 
A
Rattus 
norvegicus
50.55 1 364 39.33 8.09 34.18 31.30 4.28 -2.88
P52210 Fructose-bisphosphate aldolase 
B
Ovis aries 7.14 1 364 39.61 8.37 29.14 24.36 2.42 -4.77
P06744 Glucose-6-phosphate isomerase Homo sapiens 24.19 2 558 63.11 8.32 30.04 25.54 3.16 -4.50
P04406 Glyceraldehyde-3-phosphate 
dehydrogenase
Homo sapiens 29.25 1 335 36.03 8.46 31.64 24.20 3.27 -7.44
P00355 Glyceraldehyde-3-phosphate 
dehydrogenase
Sus scrofa 66.07 4 333 35.81 8.35 34.22 31.64 1.74 -2.58
Q5E9B1 L-lactate dehydrogenase B 
chain
Bos taurus 32.93 9 334 36.70 6.44 32.22 27.15 3.12 -5.07
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P36871 Phosphoglucomutase-1 Homo sapiens 48.40 2 562 61.41 6.76 30.09 23.34 3.22 -6.75
P00559 Phosphoglycerate kinase 1 Equus caballus 48.44 6 417 44.57 8.41 31.73 28.67 2.62 -3.06
P15259 Phosphoglycerate mutase 2 Homo sapiens 34.78 2 253 28.75 8.88 32.27 26.82 4.66 -5.45
P16290 Phosphoglycerate mutase 2 Rattus 
norvegicus
37.94 3 253 28.74 8.72 32.71 27.44 3.01 -5.27
Q2KJJ9 Fructose-1,6-bisphosphatase 
isozyme 2
Bos taurus 44.25 12 339 36.74 7.66 29.12 30.36 2.01 1.23
Creatine metabolism
Q9XSC6 Creatine kinase M-type Bos taurus 76.64 2 381 42.96 7.12 33.51 27.49 2.67 -6.02
P06732 Creatine kinase M-type Homo sapiens 48.82 3 381 43.07 7.25 33.19 30.04 1.99 -3.15
P00563 Creatine kinase M-type Oryctolagus 
cuniculus
63.52 3 381 43.09 7.12 33.16 27.08 5.20 -6.08
Q5XLD3 Creatine kinase M-type Sus scrofa 71.13 3 381 43.03 7.09 31.37 23.24 2.11 -8.12
Other metabolic process
P00571 Adenylate kinase isoenzyme 1 Sus scrofa 52.58 2 194 21.63 8.31 30.70 25.83 3.83 -4.87
P07450 Carbonic anhydrase 3 Equus caballus 13.08 4 260 29.49 7.84 29.37 26.44 2.01 -2.93
Q5S1S4 Carbonic anhydrase 3 Sus scrofa 20.00 2 260 29.39 7.85 30.25 27.78 1.99 -2.47
Q96DG6 Carboxymethylenebutenolidase 
homolog
Homo sapiens 13.06 3 245 28.03 7.18 28.36 26.25 1.89 -2.11
Cell growth and development process
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P19633 Calsequestrin-1 Rattus 
norvegicus
10.59 1 406 46.42 4.12 26.74 23.23 3.35 -3.50
Q13642 Four and a half LIM domains 
protein 1
Homo sapiens 30.96 3 323 36.24 8.97 30.84 26.57 3.34 -4.27
Q6ZMU5 Tripartite motif-containing 
protein 72
Homo sapiens 11.11 1 477 52.70 6.48 25.96 27.96 1.92 2.01
P62633 Cellular nucleic acid-binding 
protein
Homo sapiens 7.34 1 177 19.45 7.71 22.56 25.60 4.25 3.04
Other proteins
P02191 Myoglobin Cervus elaphus 77.27 2 154 17.04 7.83 34.10 30.54 2.38 -3.56
P04250 Myoglobin Lagostomus 
maximus
9.74 1 154 17.00 7.74 31.15 27.07 2.33 -4.09
P49773 Histidine triad nucleotide-binding 
protein 1
Homo sapiens 30.16 2 126 13.79 6.95 28.24 25.91 2.51 -2.33
O54724 Polymerase I and transcript 
release factor
Mus musculus 14.80 5 392 43.93 5.52 25.28 27.20 1.84 1.92
P50397 Rab GDP dissociation inhibitor 
beta
Bos taurus 11.69 4 445 50.46 6.25 23.31 25.43 1.81 2.13
338 Control and Low represent 0 and 2 mg lovastatin/kg BW, respectively. 
339 1 # AAs: number of amino acids
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340 2 MW: molecular weight
341 3 calc. pI: calculated isoelectric point
342 4 Difference: Difference in the intensity between Control and Low treatment groups. 
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344 Table 5. Differentially expressed proteins in longissimus thoracis et lumborum muscle of goats supplemented with 4mg 
345 lovastatin/ kg body weight.
UniProt 
Accession
Description Species Coverage # Unique 
Peptides
# AAs1 MW2 
[kDa]
calc. 
pI3
Control Medium -Log
p-value
Difference4
Carbohydrate metabolism
P06733 Alpha-enolase Homo sapiens 24.65 3 434 47.14 7.39 30.04 23.38 5.72 -6.66
P00883 Fructose-bisphosphate 
aldolase A
Oryctolagus 
cuniculus
59.34 5 364 39.32 8.09 34.17 28.21 3.79 -5.97
P05065 Fructose-bisphosphate 
aldolase A
Rattus norvegicus 50.55 1 364 39.33 8.09 34.18 29.39 5.10 -4.79
P06744 Glucose-6-phosphate 
isomerase
Homo sapiens 24.19 2 558 63.11 8.32 30.04 24.70 3.90 -5.34
P04406 Glyceraldehyde-3-phosphate 
dehydrogenase
Homo sapiens 29.25 1 335 36.03 8.46 31.64 26.87 3.12 -4.77
P00355 Glyceraldehyde-3-phosphate 
dehydrogenase
Sus scrofa 66.07 4 333 35.81 8.35 34.22 32.02 1.86 -2.21
Q5E9B1 L-lactate dehydrogenase B 
chain
Bos taurus 32.93 9 334 36.70 6.44 32.22 27.73 2.52 -4.48
P36871 Phosphoglucomutase-1 Homo sapiens 48.40 2 562 61.41 6.76 30.09 23.07 4.95 -7.02
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P00559 Phosphoglycerate kinase 1 Equus caballus 48.44 6 417 44.57 8.41 31.73 29.82 1.67 -1.91
P15259 Phosphoglycerate mutase 2 Homo sapiens 34.78 2 253 28.75 8.88 32.27 26.16 5.72 -6.11
P16290 Phosphoglycerate mutase 2 Rattus norvegicus 37.94 3 253 28.74 8.72 32.71 27.96 2.69 -4.75
Q2KJJ9 Fructose-1,6-bisphosphatase 
isozyme 2
Bos taurus 44.25 12 339 36.74 7.66 29.12 30.71 2.70 1.59
Creatine metabolism
Q9XSC6 Creatine kinase M-type Bos taurus 76.64 2 381 42.96 7.12 33.51 28.29 2.93 -5.23
P06732 Creatine kinase M-type Homo sapiens 48.82 3 381 43.07 7.25 33.19 28.65 4.20 -4.55
P00563 Creatine kinase M-type Oryctolagus 
cuniculus
63.52 3 381 43.09 7.12 33.16 28.82 2.94 -4.34
Q5XLD3 Creatine kinase M-type Sus scrofa 71.13 3 381 43.03 7.09 31.37 23.85 1.98 -7.52
Other metabolic process
P00571 Adenylate kinase isoenzyme 1 Sus scrofa 52.58 2 194 21.63 8.31 30.70 25.39 3.49 -5.31
Q5S1S4 Carbonic anhydrase 3 Sus scrofa 20.00 2 260 29.39 7.85 30.25 27.78 1.73 -2.47
P48644 Retinal dehydrogenase 1 Bos taurus 16.37 6 501 54.77 6.65 26.73 28.77 3.01 2.03
Cell growth and development process
P19633 Calsequestrin-1 Rattus norvegicus 10.59 1 406 46.42 4.12 26.74 24.11 2.56 -2.63
Q13642 Four and a half LIM domains 
protein 1
Homo sapiens 30.96 3 323 36.24 8.97 30.84 26.21 3.97 -4.63
P62633 Cellular nucleic acid-binding Homo sapiens 7.34 1 177 19.45 7.71 22.56 25.47 3.99 2.91
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protein
Q2UVX4 Complement C3 Bos taurus 4.21 4 1661 187.1
4
6.84 24.33 27.35 1.68 3.02
Other proteins
P49773 Histidine triad nucleotide-
binding protein 1
Homo sapiens 30.16 2 126 13.79 6.95 28.24 26.18 2.04 -2.06
Q2KHU5 O-acetyl-ADP-ribose 
deacetylase
Bos taurus 27.38 6 325 35.55 9.32 28.98 27.17 2.49 -1.82
Q09666 Neuroblast differentiation-
associated protein
Homo sapiens 4.21 5 5890 628.7
0
6.15 24.64 26.70 1.78 2.05
346 Control and Medium represent 0 and 4 mg lovastatin/kg BW, respectively. 
347 1 # AAs: number of amino acids
348 2 MW: molecular weight
349 3 calc. pI: calculated isoelectric point
350 4 Difference: Difference in the intensity between Control and Medium treatment groups.
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352 Table 6. Differentially expressed proteins in longissimus thoracis et lumborum muscle of goats supplemented with 6mg 
353 lovastatin/ kg body weight.
UniProt 
Accession
Description Species Coverage # Unique 
Peptides
# AAs1 MW2 
[kDa]
calc. 
pI3
Control High -Log p-
value 
Difference4 
Carbohydrate metabolism
P00883 Fructose-bisphosphate aldolase 
A
Oryctolagus 
cuniculus
59.34 5 364 39.32 8.09 34.17 31.71 1.74 -2.46
P05065 Fructose-bisphosphate aldolase 
A
Rattus 
norvegicus
50.55 1 364 39.33 8.09 34.18 31.90 1.50 -2.28
P08059 Glucose-6-phosphate isomerase Sus scrofa 28.49 2 558 63.09 7.99 30.02 26.84 1.53 -3.18
P13707 Glycerol-3-phosphate 
dehydrogenase [NAD(+)], 
cytoplasmic
Mus musculus 22.92 6 349 37.55 7.17 31.84 28.48 3.05 -3.36
A8BQB4 Glycogen debranching enzyme Equus 
caballus
14.94 7 1533 174.5
6
6.70 28.77 25.02 1.56 -3.75
P19858 L-lactate dehydrogenase A 
chain
Bos taurus 73.19 3 332 36.57 8.00 33.89 28.79 3.57 -5.10
Q5E9B1 L-lactate dehydrogenase B 
chain
Bos taurus 32.93 9 334 36.70 6.44 32.22 27.79 2.18 -4.43
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Q08DP0 Phosphoglucomutase-1 Bos taurus 67.44 12 562 61.55 6.81 31.52 29.40 2.02 -2.12
P36871 Phosphoglucomutase-1 Homo sapiens 48.40 2 562 61.41 6.76 30.09 24.80 2.74 -5.29
P00559 Phosphoglycerate kinase 1 Equus 
caballus
48.44 6 417 44.57 8.41 31.73 28.20 2.32 -3.53
Q7SIB7 Phosphoglycerate kinase 1 Sus scrofa 48.68 4 417 44.53 7.90 31.74 28.13 2.29 -3.60
P15259 Phosphoglycerate mutase 2 Homo sapiens 34.78 2 253 28.75 8.88 32.27 27.74 1.48 -4.53
P60174 Triosephosphate isomerase Homo sapiens 53.15 12 286 30.77 5.92 32.47 30.44 1.75 -2.03
K0J107 Malate dehydrogenase, 
mitochondrial
Felis catus 34.32 8 338 35.49 8.68 27.48 25.16 1.48 -2.32
Q99798 Aconitate hydratase, 
mitochondrial
Homo sapiens 10.64 5 780 85.37 7.61 26.52 23.92 1.48 -2.60
Creatine metabolism
Q9XSC6 Creatine kinase M-type Bos taurus 76.64 2 381 42.96 7.12 33.51 31.90 1.50 -1.62
P06732 Creatine kinase M-type Homo sapiens 48.82 3 381 43.07 7.25 33.19 30.69 2.02 -2.50
P00563 Creatine kinase M-type Oryctolagus 
cuniculus
63.52 3 381 43.09 7.12 33.16 30.81 1.87 -2.35
Other metabolic process
Q96DG6 Carboxymethylenebutenolidase 
homolog
Homo sapiens 13.06 3 245 28.03 7.18 28.36 23.90 3.60 -4.47
A4Z6H0 Adenylosuccinate synthetase Sus scrofa 17.07 1 457 50.07 8.51 26.37 22.85 1.79 -3.53
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isozyme 1
Other proteins
Q1KZF3 Beta A globin chain Capra hircus 82.76 13 145 16.01 7.30 30.85 26.54 3.04 -4.30
I1X3V1 Galectin Capra hircus 26.47 3 136 14.81 5.10 26.96 24.71 2.59 -2.25
Q99497 Protein DJ-1 Homo sapiens 43.39 7 189 19.88 6.79 29.87 27.44 1.71 -2.44
P50397 Rab GDP dissociation inhibitor 
beta
Bos taurus 11.69 4 445 50.46 6.25 23.31 26.66 2.68 3.35
354 Control and High represent 0 and 6 mg lovastatin/kg BW, respectively. 
355 1 # AAs: number of amino acids
356 2 MW: molecular weight
357 3 calc. pI: calculated isoelectric point
358 4 Difference: Difference in the intensity between Control and High treatment groups.
359
360
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361 The differentially expressed proteins were grouped on the basis of their 
362 functional role in the following categories: carbohydrate metabolism, creatine 
363 metabolism, other metabolic process, cell growth and development process and 
364 others. Most of the proteins affected were involved in carbohydrate metabolism, 
365 in which fructose-bisphosphate aldolase A, glucose-6-phosphate isomerase, L-
366 lactate dehydrogenase B chain, phosphoglucomutase-1, phosphoglycerate 
367 kinase 1, and phosphoglycerate mutase 2 were down-regulated in all lovastatin 
368 treatment groups when compared to the Control group. The muscle of the Low 
369 and Medium treatment groups showed a down-regulation in the alpha-enolase 
370 and glyceraldehyde-3-phosphate dehydrogenase when compared to the 
371 Control group. Fructose-bisphosphate aldolase B was down-regulated in the 
372 Low treatment group only, while glycerol-3-phosphate dehydrogenase [NAD+], 
373 glycogen debranching enzyme, L-lactate dehydrogenase A, malate 
374 dehydrogenase, aconitate hydratase and triosephosphate isomerase were 
375 down-regulated in the High treatment group only. Simultaneously, fructose-1,6-
376 bisphosphatase isozyme 2 was up-regulated in the Low and Medium treatment 
377 groups when compared to the Control group. 
378
379 The present findings also observed the down-regulation of creatine 
380 kinase M type in all of the lovastatin treatment groups when compared to the 
381 Control group. In addition, there were a number of proteins involved in the other 
382 metabolic processes that were identified to be differentially expressed in the 
383 lovastatin treatment groups. For example, adenylate kinase isoenzyme 1 and 
384 carbonic anhydrase 3 were down-regulated in the Low and Medium treatment 
385 groups, while carboxymethylenebutenolidase homolog was found to be down-
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386 regulated in the Low and High treatment groups. Adenylosuccinate synthetase 
387 isozyme 1 was down-regulated in the High treatment group only when 
388 compared to the Control group. Retinal dehydrogenase 1 was found to be up-
389 regulated in the Medium treatment group when compared to Control group.
390
391 There were also proteins involved in cell growth and development 
392 processes found to be differentially expressed in the present study. For instance, 
393 calsequetrin-1 and four and a half LIM domains protein 1 (FHL1) were down-
394 regulated, while cellular nucleic acid-binding protein was up-regulated in the 
395 Low and Medium treatment groups when compared to the Control group. 
396 Tripartite motif-containing protein 72 was found to be up-regulated in the Low 
397 treatment group as compared to the Control group. Complement C3 was up-
398 regulated in the Medium treatment group as compared to the Control group.
399
400 The expressions of a number of proteins involved in other processes 
401 were also identified to be regulated in the present study. Myoglobin and 
402 histidine triad nucleotide-binding protein 1 were down-regulated while 
403 polymerase I and transcript factor, and Rab GDP dissociation inhibitor beta 
404 were up-regulated in the Low treatment group when compared to the Control 
405 group. In addition, the Medium treatment group showed that histidine triad 
406 nucleotide-binding protein 1 and O-acetyl-ADP-ribose deacetylase were down-
407 regulated, while neuroblast differentiation-associated protein was up-regulated. 
408 In the High treatment group, beta A globin chain, galectin and protein DJ-1 were 
409 down-regulated while Rab GDP dissociation inhibitor beta was up-regulated.
410
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411 The differentially expressed proteins were subjected to IPA® analysis. 
412 These proteins were identified to be associated with several possible canonical 
413 pathways, which including glycolysis I, gluconeogenesis I, glucose and glucose-
414 1-phosphate degradation, creatine-phosphate biosynthesis and pyruvate 
415 fermentation to lactate. Generally, these proteins were involved in a network of 
416 carbohydrate metabolism, energy production, and skeletal and muscular system 
417 development and function.
418
419 Discussion
420 Statins are the most widely used lipid lowering agents which  inhibit 
421 HMG-CoA reductase in the cholesterol biosynthesis pathway. Nevertheless, the 
422 use of statins is reported to have adverse effects such as muscular pain, 
423 cramps and/or stiffness on skeletal muscles in humans [24]. We had previously 
424 reported that lovastatin effectively decreased methane production in goats [18]. 
425 Given the potential for myopathies at higher than recommended therapeutic 
426 doses the effects of naturally produced statins on the skeletal muscles of 
427 ruminants was a primary interest of ours. Hence, the present study examined 
428 the effects of naturally produced lovastatin on the histology and proteome 
429 profile of the representative goat skeletal muscle longissimus thoracis et 
430 lumborum. 
431
432 Histology
433 Histological examination in the present study showed that 
434 supplementation of lovastatin had light to moderate adverse effects on the 
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435 longissimus thoracis et lumborum muscle. The dose levels of the lovastatin 
436 supplementation are positively correlated to the extent of cellular damage on 
437 the skeletal muscle as reported previously [25]. Supplementation of 2mg 
438 lovastatin/kg BW induced the a low but noticeable degeneration of the muscle 
439 fiber in the goats. At higher dosages (4 and 6 mg/kg) naturally produced statin 
440 resulted in the higher degree of necrosis and degeneration, as well as larger 
441 interstitial space and vacuolization in the skeletal muscle.
442
443 Expression of myosin heavy chain and actin
444 Statin supplementation is reported to be involved in a large augmentation 
445 of reactive oxygen species production in skeletal muscle which induce 
446 mitochondrial impairments, reduce biogenesis mechanisms and result in 
447 muscular pain or myopathy [26]. Production of reactive oxygen species in the 
448 skeletal muscle may oxidize and degrade the myofibrillar proteins. Myosin 
449 heavy chain is the protein most sensitive to oxidation among the myofibrillar 
450 proteins [27]. Previous studies observed a decrease in the concentration of 
451 myosin heavy chain following the exposure to oxidants [20, 28]. High oxidative 
452 conditions cause cross-linking, polymerization and aggregate formation in 
453 myosin heavy chain through the formation of disulfide bonds, bityrosine and 
454 carbonyl derivatives [20]. In the present study, western blot analysis showed a 
455 slight degradation of myosin heavy chain only in the High treatment group. 
456 Although histological examination found that there was cellular damage in the 
457 Medium treatment group, there was no degradation on the myosin heavy chain 
458 detected. On the other hand, actin has been reported to be relatively stable 
459 under oxidative conditions [20, 28]. This may be attributable to the 
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460 inaccessibility of oxidation sites, in which myofibrillar suspensions may be 
461 masked by the interaction of actin and myosin chains [28]. The present study 
462 also demonstrated that lovastatin supplementation had no effect on the actin of 
463 skeletal muscle in goat.
464
465 Differentially expressed proteins
466 The present proteomics analysis demonstrated that supplementation of 
467 lovastatin induced modifications on the expression of a number of proteins, 
468 regardless the concentration of lovastatin. This data suggests that lovastatin 
469 had an effect on a wide range of biological functions in the muscle. Lovastatin 
470 supplementation had impaired the energy production system in the skeletal 
471 muscle, particularly in the metabolism of carbohydrate and creatine. Similar 
472 observations have been reported on the extensor digitorum longus muscle of 
473 rats treated for 2-months of 10mg atorvastatin/kg BW and 20mg fluvastatin/kg 
474 BW [29]. The impairment in the energy production system could play a major 
475 role in the development of muscle damage, which is consistent with the adverse 
476 effects observed on the longissimus thoracis et lumborum muscle through 
477 histological examination.
478
479 Carbohydrate metabolism
480 The present study showed that lovastatin supplementation down-
481 regulated proteins involving in glycolysis, gluconeogenesis and fructose 
482 metabolism. For examples, alpha-enolase, fructose-bisphosphate aldolase A, 
483 fructose-bisphosphate aldolase B, glucose-6-phosphate isomerase, 
484 glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase 1, 
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485 phosphoglycerate mutase 2 and triosephosphate isomerase are glycolytic 
486 enzymes which were down-regulated following lovastatin supplementation. In 
487 addition, phosphoglucomutase-1 that catalyzing the bi-directional inter-
488 conversion of glucose-1-phosphate and glucose-6-phosphate, was also down-
489 regulated following lovastatin supplementation. Glucose-1-phosphate is a 
490 substrate for synthesis of UDP-glucose used to synthesis a variety of cellular 
491 constituents, while glucose-6-phosphate is the first intermediate in glycolysis.
492
493 Glycolysis is an oxygen independent pathway that converts 6-carbon 
494 glucose into pyruvate. Through this metabolic process, high energy adenosine 
495 triphosphate (ATP) molecules and reduced nicotinamide adenine dinucleotide 
496 (NADH) are generated. Similar observations of down-regulation of glycolytic 
497 enzymes in the skeletal muscle have also reported previously in rat and the 
498 down-regulation of glycolytic enzymes is a symptom of energy production failure, 
499 and can contribute to muscle damage [29]. In humans, hereditary muscle 
500 glycogenoses are characterized by defective glycolytic enzymes and leads to 
501 different degree of myopathy [30]. 
502
503 Interestingly, glycogen debranching enzyme, mitochondrial malate 
504 dehydrogenase and mitochondrial aconitase hydratase were identified to be 
505 down-regulated in the High treatment group only when compared to the Control 
506 group. Glycogen debranching enzyme is an important regulatory enzyme in 
507 cellular glucose utilization and energy homeostasis. This bi-functional enzyme 
508 exhibiting both of oligotransferase (oligo-1,4 to 1,4-glucantransferase, EC 
509 2.4.1.25) and glucosidase (amylo-1,6-glucosidase, EC 3.2.1.33) activities in a 
.CC-BY 4.0 International licensenot certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (which wasthis version posted March 18, 2019. . https://doi.org/10.1101/581439doi: bioRxiv preprint 
32
510 single polypeptide chain. Along with phosphorylase, this enzyme catalyzes the 
511 complete degradation of glycogen and the release of glucose-1-phosphate and 
512 glucose [31]. Down-regulation of this enzyme indicates the reduction of glucose 
513 degraded from glycogen, and would subsequently affect the rate of glycolysis in 
514 the skeletal muscle. 
515
516 Both, mitochondrial malate dehydrogenase and aconitate hydratase are 
517 integral components in the tricarboxylic acid (TCA) cycle which playing crucial 
518 roles in energy production and biosynthesis. Malate dehydrogenase reversibly 
519 catalyzes the oxidation of malate to oxaloacetate, which is crucial in 
520 regenerating oxaloacetate that can be utilized in the TCA cycle and amino acid 
521 production [32]. Meanwhile, aconitate hydratase catalyzes the inter-conversion 
522 of citrate, isocitrate and cis-aconitate in the TCA cycle [33]. Mitochondrial 
523 aconitate hydratase is also involved in iron metabolism and is very sensitive to 
524 reactive oxygen species [34]. Large augmentation of reactive oxygen species is 
525 produced in the skeletal muscle and is associated with the induction of 
526 mitochondrial impairment [26]. The present findings indicate that a high level of 
527 lovastatin supplementation (6mg/kg BW) results in the impairment of 
528 mitochondrial function, which is in agreement with Päivä et al. [35]  reporting 
529 reduction of mitochondria volume in skeletal muscle following aggressive statin 
530 treatment. 
531
532 Meanwhile, fructose-1,6-bisphosphate isozyme 2 was up-regulated in the 
533 Low and Medium treatment groups. This enzyme catalyzes the hydrolysis of 
534 fructose-1,6-bisphosphate to fructose-6-phosphate in the gluconeogenesis [36]. 
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535 In glycolysis, fructose-6-phosphate is converted to fructose-1,6-bisphosphate by 
536 phosphofructokinase. This step is one of the rate-limiting steps in the glycolytic 
537 pathway. Up-regulation of fructose-1,6-bisphosphate isozyme 2 and the 
538 suppression of glycolysis prevent the breaking down of glucose, and 
539 subsequently the reduction in ATP production. 
540
541 Creatine metabolism
542 Generally, statin supplementation is associated with the higher 
543 concentration of creatine kinase in the blood plasma. The present study 
544 observed a down-regulation of creatine kinase following the lovastatin 
545 supplementation. Similarly, decrease of creatine kinase in the skeletal muscle of 
546 goat was also observed in rat [29]. Creatine kinase is an enzyme catalyzes the 
547 conversion of creatine to phosphocreatine by utilizing ATP. This enzyme also 
548 catalyzes the reverse reaction to produce phosphocreatine and ATP. In tissues 
549 utilizing a large amount of ATP such as skeletal muscle, creatine kinase 
550 /phosphocreatine system plays a complex and multi-faceted role in regulating 
551 cellular energy homeostasis [37]. The ATP regeneration capacity of creatine 
552 kinase is very high and considerably exceeds both cellular utilization and 
553 replenishment through glycolysis and oxidative phosphorylation [37]. 
554 Interestingly, previous study showed that the transgenic mice lacking either the 
555 cytoplasmic or mitochondrial creatine kinase may develop muscle atrophy [38]. 
556 Together with proteins involved in carbohydrate metabolism, down-regulation of 
557 creatine kinase indicated an impairment to the energy production system, which 
558 may develop statin myopathy.
559
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560 Other metabolic process
561 Down-regulation of adenylate kinase isozyme 1, adenylosuccinate 
562 synthethase isozyme 1 and carbonic anhydrase 3 may impair the energy 
563 production in the skeletal muscle. Adenylate kinase isozyme 1 and 
564 adenylosuccinate synthethase isozyme 1 play an important role in cellular 
565 energy homeostasis, and more specifically in adenine nucleotide metabolism. 
566 Adenylate kinase isozyme 1 catalyzes the reversible transfer of phosphate 
567 between ATP and adenosine monophosphate (AMP), while adenylosuccinate 
568 synthethase isozyme 1 interconverts inosine monophosphate (IMP) and AMP to 
569 regulate nucleotide levels in the tissue, and which contributes to the regulation 
570 of glycolysis. Meanwhile, the lack of carbonic anhydrase 3 is suggested to 
571 impair mitochondrial ATP synthesis in the gastrocnemius muscle of rat [39]. 
572 Furthermore, carbonic anhydrase 3 is also shown to provide protection to the 
573 cells against free radicals [40].
574
575 Retinal dehydrogenase 1, glycerol-3-phosphate dehydrogenase [NAD+], 
576 L-lactate dehydrogenase A chain and L-lactate dehydrogenase B chain are 
577 involved in redox cofactor metabolism which plays a central role in meeting 
578 cellular redox requirements of proliferating mammalian cells. Retinal 
579 dehydrogenase 1 converts retinaldehyde to retinoic acid, which directly 
580 catalyzes the regeneration of NADH. Glycerol-3-phosphate dehydrogenase 
581 catalyzes the reversible conversion of dihydroxyacetone phosphate to glycerol-
582 3-phosphate, which involves the redox reaction of NADH and NAD+. Meanwhile, 
583 lactate dehydrogenase catalyzes the conversion of pyruvate into lactate. 
584 Usually, a large amount of lactate is generated in proliferating cells to allow high 
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585 glycolytic flux to support the generation of ATP and biosynthetic precursors [41]. 
586 At the same time, generation of lactate also involves the conversion of NADH to 
587 NAD+ by lactate dehydrogenase. NAD+ is crucial as it is directly used to oxidize 
588 precursors of some nucleotides and amino acids, and also many intermediates 
589 of NAD+-dependent pathway are important precursors for biosynthesis [42]. 
590 Reduction in these proteins may affect the NADP dependent pathways, then 
591 blocking the ATP production pathways.
592
593 Cell growth and development process
594 Reduction in the expression of calsequestrin and FHL1, that are involved 
595 in muscle development, was associated with the muscle damage. Calsequestrin 
596 is a Ca2+-binding protein, which has been showed to be decreased in 
597 dystrophic mouse skeletal muscle [43], while mutation in FHL1 gene is 
598 associated with myopathy [44]. FHL1 is a multifunctional protein likely to be 
599 involved in ion channel binding and muscle development. Furthermore, 
600 transport proteins such as beta A globin chain, myoglobin and polymerase I and 
601 transcript release factor were also down-regulated following lovastatin 
602 supplementation. Polymerase I and transcript release factor is a protein 
603 associated with processes of vesicular transport and cholesterol homeostasis 
604 [45].
605
606 The present findings also identified proteins involved in the muscle tissue 
607 development (such as complement C3, tripartite motif-containing proteins 72, 
608 and cellular nucleic acid binding protein) which were up-regulated following 
609 lovastatin supplementation. Complement C3 is shown to be activated in skeletal 
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610 muscle injury and plays a key role in the regeneration of muscle tissue [46, 47]. 
611 Tripartite motif-containing proteins are expressed in the skeletal muscle to 
612 regulate muscle coordination, atrophy and repair. This protein plays an vital role 
613 as a negative regulator of IGF-induced muscle differentiation [48]. Meanwhile, 
614 cellular nucleic acid binding protein has been reported recently that its 
615 modifications which are indicated to play a role in myotonic dystrophy type 2 
616 disease might result in muscle atrophy through affecting myofiber membrane 
617 function [49]. Together with Rab GDP dissociation inhibitor beta which involved 
618 in the regulation of vesicle-mediated cellular transport [50], up-regulation of 
619 these proteins in the present study indicated that the mechanism associated 
620 with tissue regeneration or repair was activated in the muscle tissue.
621
622 Other proteins
623 In addition to the energy production system, proteins involved in other 
624 cellular processes were also affected by lovastatin. Proteins such as galectins, 
625 histidine triad nucleotide-binding protein 1 and Protein DJ-1, which are in 
626 involved in the regulation of the apoptotic pathway, were also down-regulated 
627 following lovastatin supplementation. Galectins have a diverse range of 
628 biological functions including regulation of pre-mRNA splicing, cell adhesion, 
629 cell growth, differentiation, apoptosis and cell cycle [51], while protein DJ-1 
630 plays an important role in cell protection against oxidative stress and cell death 
631 [52].
632
633 Taken together, the present study has shown that lovastatin 
634 supplementation down-regulates proteins involved in the energy production 
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635 system (particularly the glycolytic pathway and creatine metabolism), regardless 
636 of the concentration of lovastatin. Supplementation with a high concentration of 
637 lovastatin (6mg/ kg BW) could further impair the TCA cycle. Moreover, 
638 supplementation of lovastatin also activates tissue regeneration or repair in the 
639 muscle tissue. Furthermore, changes in the expression of proteins involved in 
640 apoptosis and oxidative damage suggests an accentuated sensitivity of statin-
641 treated muscle to oxidative stress. Oxidative stress can promote increased 
642 proteolysis and depress protein synthesis, and trigger many conditions 
643 associated with muscle wasting [53]. Such perturbation in energy metabolism 
644 and ATP synthesis may have profound effects on protein synthesis and 
645 contribute to metabolic stress, which could play a major role in the development 
646 of myopathy.
647
648 Conclusions
649 Histology scores indicated increasing muscle damage to the longissimus 
650 thoracis et lumborum muscle of goats supplemented with increasing dosages, 
651 particularly at 6mg/kg BW, of naturally produced lovastatin. In addition, western 
652 blot analysis indicated that the immunoreactivity of myosin heavy chain was 
653 only degraded in the muscle of goats supplemented with 6mg lovastatin/kg BW. 
654 Proteomics analysis revealed that lovastatin supplementation induced complex 
655 modifications to the carbohydrate metabolism, energy production, and skeletal 
656 and muscular system development of skeletal muscle of goats which may have 
657 contributed to the observed skeletal muscle damage. Putting together results of 
658 the above three analyses, it is clear that supplementation of naturally-produced 
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659 lovastatin at 6 mg/kg BW is too high, which can adversely affecting health and 
660 wellbeing of the animals.
661
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